2022
Effect of Implementation Facilitation to Promote Adoption of Medications for Addiction Treatment in US HIV Clinics
Edelman EJ, Gan G, Dziura J, Esserman D, Porter E, Becker WC, Chan PA, Cornman DH, Helfrich CD, Reynolds J, Yager JE, Morford KL, Muvvala SB, Fiellin DA. Effect of Implementation Facilitation to Promote Adoption of Medications for Addiction Treatment in US HIV Clinics. JAMA Network Open 2022, 5: e2236904. PMID: 36251291, PMCID: PMC9577676, DOI: 10.1001/jamanetworkopen.2022.36904.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcoholismAnalgesics, OpioidFemaleHIV InfectionsHumansMaleMiddle AgedOpioid-Related DisordersTobacco Use DisorderConceptsTobacco use disorderHIV clinicOpioid use disorderUse disordersAlcohol use disorderAddiction treatmentControl periodImplementation facilitationAdoption of medicationsMulticomponent implementation strategyProvision of MOUDUS HIV clinicsMaintenance periodElectronic health record dataHealth record dataEvaluation periodAdult patientsMean ageClinical trialsMAIN OUTCOMEClinicMOUDPatientsDisordersPatient incentivesPatients' perspectives of medications for addiction treatment in HIV clinics: A qualitative study
Morford KL, Muvvala SB, Chan PA, Cornman DH, Doernberg M, Porter E, Virata M, Yager JE, Fiellin DA, Edelman EJ. Patients' perspectives of medications for addiction treatment in HIV clinics: A qualitative study. Journal Of Substance Use And Addiction Treatment 2022, 139: 108767. PMID: 35341613, PMCID: PMC9187601, DOI: 10.1016/j.jsat.2022.108767.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidHIV InfectionsHumansMass ScreeningQualitative ResearchSubstance-Related DisordersConceptsSubstance use disordersHIV clinicAddiction treatmentSubstance useEvidence-based medicationsMedication treatment optionsMedication side effectsHealth Services frameworkFocus groupsHIV cliniciansTreatment optionsMultidisciplinary screeningChronic diseasesPatient educationPatient's perspectivePromoting ActionStudy populationDisorder careSide effectsUse disordersPatient receptivityQualitative studyOverall healthClinicKnowledge deficits
2021
Maternal opioid use disorder: Placental transcriptome analysis for neonatal opioid withdrawal syndrome
Radhakrishna U, Nath SK, Vishweswaraiah S, Uppala LV, Forray A, Muvvala SB, Mishra NK, Southekal S, Guda C, Govindamangalam H, Vargas D, Gardella WG, Crist RC, Berrettini WH, Metpally RP, Bahado-Singh RO. Maternal opioid use disorder: Placental transcriptome analysis for neonatal opioid withdrawal syndrome. Genomics 2021, 113: 3610-3617. PMID: 34352367, DOI: 10.1016/j.ygeno.2021.08.001.Peer-Reviewed Original ResearchConceptsNeonatal opioid withdrawal syndromeOpioid withdrawal syndromeWithdrawal syndromePrenatal opioid exposureOpioid use disorderPlacentas of infantsPlacental tissue samplesP-valueIngenuity Pathway AnalysisOpioid exposureUse disordersUnexposed controlsFDR p-valueGenes CYP1A1Tissue samplesSyndromePathway analysisCYP1A1NewbornsInfantsEtiologyApoBPlacentaGenesGRIN2APlacental DNA methylation profiles in opioid-exposed pregnancies and associations with the neonatal opioid withdrawal syndrome
Radhakrishna U, Vishweswaraiah S, Uppala LV, Szymanska M, Macknis J, Kumar S, Saleem-Rasheed F, Aydas B, Forray A, Muvvala SB, Mishra NK, Guda C, Carey DJ, Metpally RP, Crist RC, Berrettini WH, Bahado-Singh RO. Placental DNA methylation profiles in opioid-exposed pregnancies and associations with the neonatal opioid withdrawal syndrome. Genomics 2021, 113: 1127-1135. PMID: 33711455, DOI: 10.1016/j.ygeno.2021.03.006.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidArtificial IntelligenceDNA MethylationFemaleHumansInfantInfant, NewbornNeonatal Abstinence SyndromePlacentaPregnancyConceptsNeonatal opioid withdrawal syndromeOpioid withdrawal syndromeIngenuity Pathway AnalysisWithdrawal syndromeOpioid-exposed pregnanciesPlacental tissue samplesOpioid abusePlacental tissueTissue samplesPregnancyMethylation dysregulationGenome-wide methylation analysisSyndromeInfantsPathway analysisAUCDNA methylation profilesMethylation profilesGroupPathophysiologyTherapyStrong evidence
2019
Medications for Maintenance Treatment of Opioid Use Disorder in Adolescents: A Narrative Review and Assessment of Clinical Benefits and Potential Risks.
Camenga DR, Colon-Rivera HA, Muvvala SB. Medications for Maintenance Treatment of Opioid Use Disorder in Adolescents: A Narrative Review and Assessment of Clinical Benefits and Potential Risks. Journal Of Studies On Alcohol And Drugs 2019, 80: 393-402. PMID: 31495374, DOI: 10.15288/jsad.2019.80.393.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdolescent BehaviorAnalgesics, OpioidBuprenorphineHumansMethadoneNaltrexoneOpiate Substitution TreatmentOpioid-Related DisordersConceptsTreatment of OUDOpioid use disorderUse disordersClinical benefitTreatment retentionUntreated opioid use disorderHeroin use disorderEvidence-based treatmentsPotential riskLittle published evidenceBuprenorphine treatmentOpioid abstinenceMaintenance treatmentAdolescent patientsTreatment needsMedicationsMethadoneNarrative reviewHealthcare professionalsPublished evidenceBuprenorphineNaltrexoneTreatmentDisordersEfficacy